RT Journal Article
SR Electronic
T1 Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review
JF BMJ Open Ophthalmology
JO BMJ Open Ophth
FD BMJ Publishing Group Ltd
SP e000398
DO 10.1136/bmjophth-2019-000398
VO 4
IS 1
A1 Saira Khanna
A1 Rahul Komati
A1 David A Eichenbaum
A1 Ishani Hariprasad
A1 Thomas A Ciulla
A1 Seenu M Hariprasad
YR 2019
UL http://bmjophth.bmj.com/content/4/1/e000398.abstract
AB Age-related macular degeneration is the leading cause of vision loss in the developed world, with the expected number of affected elderly individuals reaching 17.8 million. Antivascular endothelial growth factor (anti-VEGF) injection therapy has been instrumental in treating a disease process that was previously thought to be untreatable. Over the past two decades, landmark studies have demonstrated the efficacy of different anti-VEGF medications and investigated the optimal dosing regimen and delivery mechanism to increase overall vision and minimise patient burden. In this review, we outline landmark neovascular age-related macular degeneration clinical trials that have demonstrated level 1 evidence for its usage or have contributed to the understanding of how to dose these agents.